<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-02-10">10 February 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">Ariane</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
							<email>ariane.herrick@manchester.ac.uk</email>
							<affiliation key="aff2">
								<orgName type="department">Centre for Musculoskeletal Research</orgName>
								<orgName type="institution" key="instit1">The University of Manchester</orgName>
								<orgName type="institution" key="instit2">Salford Royal NHS Foundation Trust</orgName>
								<orgName type="institution" key="instit3">Manchester Academic Health Science Centre</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">NIHR Manchester Musculoskeletal Biomedical Research Unit</orgName>
								<orgName type="institution" key="instit2">Central Manchester NHS Foundation Trust</orgName>
								<orgName type="institution" key="instit3">Manchester Academic Health Science Centre</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Department</orgName>
								<orgName type="institution" key="instit1">&quot;Grigore T. Popa&quot; University of Medicine and Pharmacy</orgName>
								<orgName type="institution" key="instit2">Clinical Rehabilitation Hospital</orgName>
								<address>
									<settlement>Iași</settlement>
									<country key="RO">Romania</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Xiaoyan</forename><surname>Pan</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Centre for Musculoskeletal Research</orgName>
								<orgName type="institution" key="instit1">The University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Academic Health Science Centre</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sébastien</forename><surname>Peytrignet</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Centre for Musculoskeletal Research</orgName>
								<orgName type="institution" key="instit1">The University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Academic Health Science Centre</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mark</forename><surname>Lunt</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Centre for Musculoskeletal Research</orgName>
								<orgName type="institution" key="instit1">The University of Manchester</orgName>
								<orgName type="institution" key="instit2">Manchester Academic Health Science Centre</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roger</forename><surname>Hesselstrand</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Lund University</orgName>
								<address>
									<settlement>Lund</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luc</forename><surname>Mouthon</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Service de Médecine Interne</orgName>
								<orgName type="laboratory">Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique</orgName>
								<orgName type="institution" key="instit1">Hôpital Cochin</orgName>
								<orgName type="institution" key="instit2">Université Paris Descartes</orgName>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution">Assistance Publique-Hôpitaux de Paris (AP-HP)</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alan</forename><surname>Silman</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences</orgName>
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<settlement>Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Edith</forename><surname>Brown</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Member of Steering Committee</orgName>
								<orgName type="department" key="dep2">contact via Professor Herrick</orgName>
								<orgName type="institution">The University of Manchester</orgName>
								<address>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">László</forename><surname>Czirják</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Rheumatology and Immunology</orgName>
								<orgName type="department" key="dep2">Medical Center</orgName>
								<orgName type="institution">University of Pécs</orgName>
								<address>
									<settlement>Pecs</settlement>
									<country key="HU">Hungary</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jörg</forename><forename type="middle">H W</forename><surname>Distler</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Internal Medicine 3</orgName>
								<orgName type="institution">University of Erlangen-Nuremberg</orgName>
								<address>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oliver</forename><surname>Distler</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">University of Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kim</forename><surname>Fligelstone</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Royal Free London NHS Foundation Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">William</forename><forename type="middle">J</forename><surname>Gregory</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution" key="instit1">Rehabilitation Services</orgName>
								<orgName type="institution" key="instit2">Salford Royal NHS Foundation Trust</orgName>
								<address>
									<settlement>Salford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rachel</forename><surname>Ochiel</surname></persName>
							<affiliation key="aff13">
								<orgName type="institution">Royal Free London NHS Foundation Trust</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Madelon</forename><surname>Vonk</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of the Rheumatic Diseases</orgName>
								<orgName type="institution">Radboud University Nijmegen Medical Centre</orgName>
								<address>
									<settlement>Nijmegen</settlement>
									<country>The Netherlands 14 Rheumatology</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Codrina</forename><surname>Ancuţa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Voon</forename><forename type="middle">H</forename><surname>Ong</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Centre for Rheumatology and Connective Tissue Diseases</orgName>
								<orgName type="institution">UCL Division of Medicine</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dominique</forename><surname>Farge</surname></persName>
							<affiliation key="aff18">
								<orgName type="laboratory">Maladies Auto-immunes et Pathologie Vasculaire</orgName>
								<orgName type="institution">Unité Clinique de Médecine Interne</orgName>
								<address>
									<addrLine>UF 04</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="institution" key="instit1">Hôpital Saint-Louis</orgName>
								<orgName type="institution" key="instit2">AP-HP Assistance Publique des Hôpitaux de Paris</orgName>
								<orgName type="institution" key="instit3">INSERM UMRS</orgName>
								<orgName type="institution" key="instit4">Paris Denis Diderot University</orgName>
								<address>
									<postCode>1160</postCode>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marie</forename><surname>Hudson</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Lady Davis Institute</orgName>
								<orgName type="institution" key="instit1">Jewish General Hospital</orgName>
								<orgName type="institution" key="instit2">McGill University</orgName>
								<address>
									<settlement>Montreal</settlement>
									<country key="CA">Canada</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marco</forename><surname>Matucci-Cerinic</surname></persName>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department Experimental and Clinical Medicine</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology AOUC</orgName>
								<orgName type="institution">University of Florence</orgName>
								<address>
									<settlement>Florence</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexandra</forename><surname>Balbir- Gurman</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Øyvind</forename><surname>Midtvedt</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Rappaport Faculty of Medicine</orgName>
								<orgName type="laboratory">Shine Rheumatology Unit</orgName>
								<orgName type="institution">Rambam Heath Care Campus</orgName>
								<address>
									<settlement>Haifa</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
							<affiliation key="aff23">
								<orgName type="institution" key="instit1">Rheumatology Unit</orgName>
								<orgName type="institution" key="instit2">Oslo University Hospital Rikshospitalet</orgName>
								<address>
									<settlement>Oslo</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alison</forename><forename type="middle">C</forename><surname>Jordan</surname></persName>
							<affiliation key="aff24">
								<orgName type="institution" key="instit1">Queen Elizabeth Hospital Birmingham</orgName>
								<orgName type="institution" key="instit2">UHB Foundation Trust</orgName>
								<address>
									<settlement>Birmingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paresh</forename><surname>Jobanputra</surname></persName>
							<affiliation key="aff24">
								<orgName type="institution" key="instit1">Queen Elizabeth Hospital Birmingham</orgName>
								<orgName type="institution" key="instit2">UHB Foundation Trust</orgName>
								<address>
									<settlement>Birmingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wendy</forename><surname>Stevens</surname></persName>
							<affiliation key="aff25">
								<orgName type="institution">St Vincent&apos;s Hospital</orgName>
								<address>
									<settlement>Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pia</forename><surname>Moinzadeh</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Department for Dermatology</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<addrLine>Kerpenerstr. 62</addrLine>
									<settlement>Köln</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frances</forename><forename type="middle">C</forename><surname>Hall</surname></persName>
							<affiliation key="aff27">
								<orgName type="institution">Cambridge University NHS Hospital Foundation Trust</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Agard</surname></persName>
							<affiliation key="aff28">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution" key="instit1">Hôtel-Dieu Hospital</orgName>
								<orgName type="institution" key="instit2">University of Nantes</orgName>
								<address>
									<settlement>Nantes</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marina</forename><forename type="middle">E</forename><surname>Anderson</surname></persName>
							<affiliation key="aff29">
								<orgName type="institution" key="instit1">University of Liverpool</orgName>
								<orgName type="institution" key="instit2">Aintree University Hospital</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisabeth</forename><surname>Diot</surname></persName>
							<affiliation key="aff30">
								<orgName type="department">Service de Médecine Interne</orgName>
								<orgName type="institution">Hôpital Bretonneau Tours Cedex</orgName>
								<address>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rajan</forename><surname>Madhok</surname></persName>
							<affiliation key="aff31">
								<orgName type="institution" key="instit1">Centre for Rheumatic Diseases</orgName>
								<orgName type="institution" key="instit2">Glasgow Royal Infirmary</orgName>
								<address>
									<settlement>Glasgow</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mohammed</forename><surname>Akil</surname></persName>
							<affiliation key="aff32">
								<orgName type="institution">Sheffield Teaching Hospitals</orgName>
								<address>
									<settlement>Sheffield</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Maya</forename><forename type="middle">H</forename><surname>Buch</surname></persName>
							<affiliation key="aff33">
								<orgName type="institution" key="instit1">Leeds Institute of Rheumatic and Musculoskeletal Medicine</orgName>
								<orgName type="institution" key="instit2">University of Leeds</orgName>
								<orgName type="institution" key="instit3">NIHR Leeds Musculoskeletal Biomedical Research Unit</orgName>
								<orgName type="institution" key="instit4">Leeds Teaching Hospitals NHS Trust</orgName>
								<address>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lorinda</forename><surname>Chung</surname></persName>
							<affiliation key="aff34">
								<orgName type="institution">Stanford University</orgName>
								<address>
									<settlement>Stanford</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nemanja</forename><surname>Damjanov</surname></persName>
							<affiliation key="aff35">
								<orgName type="department">Institute of Rheumatology</orgName>
								<orgName type="institution">University of Belgrade School of Medicine</orgName>
								<address>
									<settlement>Belgrade</settlement>
									<country key="RS">Serbia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Harsha</forename><surname>Gunawardena</surname></persName>
							<affiliation key="aff36">
								<orgName type="department">Clinical and Academic Rheumatology</orgName>
								<orgName type="institution">North Bristol NHS Trust</orgName>
								<address>
									<settlement>Bristol</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Lanyon</surname></persName>
							<affiliation key="aff37">
								<orgName type="institution">Nottingham University Hospitals NHS Trust, and Nottingham NHS Treatment Centre</orgName>
								<address>
									<settlement>Nottingham</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yasmeen</forename><surname>Ahmad</surname></persName>
							<affiliation key="aff38">
								<orgName type="institution">Peter Maddison Rheumatology Centre</orgName>
								<address>
									<settlement>Llandudno</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Kuntal</forename><surname>Chakravarty</surname></persName>
							<affiliation key="aff39">
								<orgName type="institution">Queens Hospital</orgName>
								<address>
									<settlement>Romford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Søren</forename><surname>Jacobsen</surname></persName>
							<affiliation key="aff40">
								<orgName type="department">Center for Rheumatology and Spine Diseases</orgName>
								<orgName type="institution" key="instit1">University of Copenhagen</orgName>
								<orgName type="institution" key="instit2">Copenhagen Lupus and Vasculitis Clinic</orgName>
								<address>
									<settlement>Rigshospitalet, Copenhagen</settlement>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><forename type="middle">J</forename><surname>Macgregor</surname></persName>
							<affiliation key="aff41">
								<orgName type="department">Norwich Medical School</orgName>
								<orgName type="institution">University of East Anglia</orgName>
								<address>
									<settlement>Norwich</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Neil</forename><surname>Mchugh</surname></persName>
							<affiliation key="aff42">
								<orgName type="institution">Royal National Hospital for Rheumatic Diseases</orgName>
								<address>
									<settlement>Bath</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ulf</forename><surname>Müller-Ladner</surname></persName>
							<affiliation key="aff43">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">Justus-Liebig University Giessen</orgName>
								<address>
									<settlement>Bad Nauheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gabriela</forename><surname>Riemekasten</surname></persName>
							<affiliation key="aff44">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">University of Lübeck</orgName>
								<address>
									<settlement>Lübeck</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Becker</surname></persName>
							<affiliation key="aff45">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">University Hospital Charité Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Janet</forename><surname>Roddy</surname></persName>
							<affiliation key="aff46">
								<orgName type="department">Department of Rheumatology</orgName>
								<orgName type="institution">Royal Perth Hospital</orgName>
								<address>
									<settlement>Perth</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><forename type="middle">E</forename><surname>Carreira</surname></persName>
							<affiliation key="aff47">
								<orgName type="institution">Servicio de Reumatologia. Hospital Universitario</orgName>
								<address>
									<addrLine>12 de Octubre</addrLine>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anne</forename><forename type="middle">Laure</forename><surname>Fauchais</surname></persName>
							<affiliation key="aff48">
								<orgName type="department">Internal Medicine Unit</orgName>
								<orgName type="institution">Limoges University Hospital</orgName>
								<address>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Hachulla</surname></persName>
							<affiliation key="aff49">
								<orgName type="department" key="dep1">Département de Médecine Interne et Immunologie Clinique</orgName>
								<orgName type="department" key="dep2">FHU Immune-Mediated Inflammatory Diseases and Targeted Therapies</orgName>
								<orgName type="institution" key="instit1">Centre National de Référence Maladies Systémiques etAuto-immunes Rares</orgName>
								<orgName type="institution" key="instit2">Université de Lille</orgName>
								<address>
									<postCode>U995</postCode>
									<settlement>Inserm, Lille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jennifer</forename><surname>Hamilton</surname></persName>
							<affiliation key="aff50">
								<orgName type="institution">Gateshead Hospitals Foundation Trust</orgName>
								<address>
									<settlement>Gateshead</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Murat</forename><surname>İnanç</surname></persName>
							<affiliation key="aff51">
								<orgName type="department" key="dep1">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">John</forename><forename type="middle">S</forename><surname>Mclaren</surname></persName>
							<affiliation key="aff52">
								<orgName type="institution" key="instit1">Fife Rheumatic Diseases Unit</orgName>
								<orgName type="institution" key="instit2">Whyteman&apos;s Brae Hospital</orgName>
								<address>
									<settlement>Kirkcaldy</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jacob</forename><forename type="middle">M</forename><surname>Van Laar</surname></persName>
							<affiliation key="aff53">
								<orgName type="department">Department of Rheumatology and Clinical Immunology</orgName>
								<orgName type="institution">UMC Utrecht</orgName>
								<address>
									<settlement>Utrecht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sanjay</forename><surname>Pathare</surname></persName>
							<affiliation key="aff54">
								<orgName type="institution">James Cook University Hospital</orgName>
								<address>
									<settlement>Middlesbrough</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susannah</forename><surname>Proudman</surname></persName>
							<affiliation key="aff55">
								<orgName type="department">Discipline of Medicine</orgName>
								<orgName type="institution" key="instit1">Rheumatology Unit</orgName>
								<orgName type="institution" key="instit2">Royal Adelaide Hospital</orgName>
								<orgName type="institution" key="instit3">University of Adelaide</orgName>
								<address>
									<settlement>Adelaide</settlement>
									<country>South Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><surname>Rudin</surname></persName>
							<affiliation key="aff56">
								<orgName type="department">Department of Rheumatology and Inflammation Research</orgName>
								<orgName type="institution">The Sahlgrenska Academy at Gothenburg University</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joanne</forename><surname>Sahhar</surname></persName>
							<affiliation key="aff57">
								<orgName type="department">Monash Centre for Inflammatory Diseases</orgName>
								<orgName type="institution">Monash University</orgName>
								<address>
									<settlement>Clayton, Melbourne</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Brigitte</forename><surname>Coppere</surname></persName>
							<affiliation key="aff58">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution">Hôpital Edouard Herriot</orgName>
								<address>
									<settlement>Lyon</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff59">
								<orgName type="department">56 Department of Internal Medicine</orgName>
								<orgName type="institution">Foundation Hospital Saint Joseph</orgName>
								<address>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>Serratrice</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Tom</forename><surname>Sheeran</surname></persName>
							<affiliation key="aff60">
								<orgName type="institution">Cannock Chase Hospital</orgName>
								<address>
									<settlement>Cannock</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Douglas</forename><forename type="middle">J</forename><surname>Veale</surname></persName>
							<affiliation key="aff61">
								<orgName type="institution">St Vincent&apos;s University Hospital</orgName>
								<address>
									<settlement>Dublin</settlement>
									<country key="IE">Ireland</country>
								</address>
							</affiliation>
							<affiliation key="aff62">
								<orgName type="department">59 Department of Internal Medicine</orgName>
								<orgName type="institution">Centre Hospitalier Lyon Sud</orgName>
								<address>
									<addrLine>Pierre Benite</addrLine>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claire</forename><surname>Grange</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Georges-Selim</forename><surname>Trad</surname></persName>
							<affiliation key="aff63">
								<orgName type="institution" key="instit1">Internal Medecine</orgName>
								<orgName type="institution" key="instit2">Ambroise Paré Hospital</orgName>
								<address>
									<settlement>Boulogne Billancourt</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christopher</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Centre for Rheumatology and Connective Tissue Diseases</orgName>
								<orgName type="institution">UCL Division of Medicine</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Herrick</forename><surname>Al</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">University of Manchester</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Salford Royal NHS Foundation Trust</orgName>
								<orgName type="institution" key="instit2">Manchester Academic Health Science Centre</orgName>
								<address>
									<postCode>M13 9PT</postCode>
									<settlement>Manchester</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-02-10">10 February 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">7625FEE4672C837133430F9F1CAA3367</idno>
					<idno type="DOI">10.1136/annrheumdis-2016-210503</idno>
					<note type="submission">Received 12 September 2016 Revised 24 November 2016 Accepted 25 November 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Objectives The rarity of early diffuse cutaneous systemic sclerosis (dcSSc) makes randomised controlled trials very difficult.</s><s>We aimed to use an observational approach to compare effectiveness of currently used treatment approaches.</s><s>Methods This was a prospective, observational cohort study of early dcSSc (within three years of onset of skin thickening).</s><s>Clinicians selected one of four protocols for each patient: methotrexate, mycophenolate mofetil (MMF), cyclophosphamide or 'no immunosuppressant'.</s><s>Patients were assessed three-monthly for up to 24 months.</s><s>The primary outcome was the change in modified Rodnan skin score (mRSS).</s><s>Confounding by indication at baseline was accounted for using inverse probability of treatment (IPT) weights.</s><s>As a secondary outcome, an IPT-weighted Cox model was used to test for differences in survival.</s><s>Results Of 326 patients recruited from 50 centres, 65 were prescribed methotrexate, 118 MMF, 87 cyclophosphamide and 56 no immunosuppressant.</s><s>276 (84.7%) patients completed 12 and 234 (71.7%) 24 months follow-up (or reached last visit date).</s><s>There were statistically significant reductions in mRSS at 12 months in all groups: −4.0 (−5.2 to −2.7) units for methotrexate, −4.1 (−5.3 to −2.9) for MMF, −3.3 (−4.9 to −1.7) for cyclophosphamide and −2.2 (−4.0 to −0.3) for no immunosuppressant ( p value for between-group differences=0.346).</s><s>There were no statistically significant differences in survival between protocols before ( p=0.389) or after weighting ( p=0.440), but survival was poorest in the no immunosuppressant group (84.0%) at 24 months.</s><s>Conclusions These findings may support using immunosuppressants for early dcSSc but suggest that overall benefit is modest over 12 months and that better treatments are needed.</s><s>Trial registration number NCT02339441.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>The diffuse cutaneous subtype of systemic sclerosis (dcSSc) is rare (SSc incidence is around 10-20/ million/year, <ref type="bibr" target="#b17">1</ref> of whom approximately 25% will have diffuse disease) but carries high morbidity and mortality due to early internal organ involvement and rapidly progressive, painful skin thickening.</s><s>Also, 5-year and 10-year survival rates, although improving, are in the order of 68% and 50%, respectively. <ref type="bibr">2 3</ref></s><s>t present, there is no drug known to favourably influence disease course.</s><s>Randomised controlled trials (RCTs) have historically been confounded by disease rarity (only small numbers of patients are recruited, often over long periods) and strict entry criteria meaning that severe cases are often excluded. <ref type="bibr" target="#b20">4</ref></s><s>These strict criteria further restrict sample sizes and limit generalisability.</s><s>Therefore, although RCTs represent a gold standard for assessing drug efficacy, results may not be applicable to real-life clinical settings. <ref type="bibr" target="#b21">5</ref></s><s>Small trials run the risk of being underpowered, thus potentially yielding false-negative results. <ref type="bibr" target="#b22">6</ref></s><s>he past three decades have seen a number of promising treatments for early dcSSc failing to meet efficacy end points in RCTs: examples include methotrexate (multinational, 71 patients) <ref type="bibr" target="#b23">7</ref> and anti-transforming growth factor β1 antibody therapy (multinational, 45 patients). <ref type="bibr" target="#b24">8</ref></s><s> further difficulty in recruiting into RCTs of early dcSSc is that many clinicians have reservations about placebo therapy in a potentially life-threatening disease and favour immunosuppression, consistent with the European League Against Rheumatism (EULAR) recommendations, which advocate methotrexate for skin manifestations <ref type="bibr" target="#b25">9</ref> in early dcSSc, although this agent has been shown to be of only limited efficacy.</s><s><ref type="bibr" target="#b23">7</ref> Immunosuppressants are potentially hazardous, especially in patients prone to internal organ disease and infection.</s></p><p><s>Against this background, our aim was to compare, using an observational approach, the effectiveness of standard treatment approaches (mainly immunosuppressant treatments but including a 'no immunosuppressant' option to reflect that some patients or clinicians may choose this approach) in the early management of patients with dcSSc, capturing entry and outcome data in a systematic way.</s><s>Modern statistical approaches allow robust interrogations of prospective observational studies, as an adjunct to, or even substitute for, RCTs in rare diseases, <ref type="bibr" target="#b26">10</ref> although the potential of these novel approaches has not yet been realised. <ref type="bibr" target="#b27">11</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study design</head><p><s>The European Scleroderma Observational Study (ESOS) was a prospective, observational cohort study (ClinicalTrials.gov</s><s>identifier: NCT02339441), in which standardised data were collected at study entry and at follow-up visits, and entered electronically by investigators at each centre into an electronic case record form.</s><s>All data were checked by the project coordinator and any inconsistencies were discussed with the chief investigator and (if appropriate) the local principal investigator.</s><s>The main inclusion criteria were early dcSSc (skin involvement proximal to elbow, knee, face, neck <ref type="bibr" target="#b28">12</ref> and within three years of the onset of skin thickening) and age &gt;18 years.</s><s>Exclusion criteria were previous stem cell transplantation, previous immunosuppressant treatment for &gt;4 months or use of any immunosuppressant drug other than methotrexate, mycophenolate mofetil (MMF) or cyclophosphamide within the month prior to study entry.</s></p><p><s>Clinicians selected the protocol of their choice for each patient.</s><s>The recommended treatment protocols, as decided by the Steering Committee to reflect international best clinical practice, were 1. Methotrexate (oral or subcutaneous with a target dose of 20-25 mg weekly).</s><s>2. MMF (500 mg twice daily for 2 weeks increasing to 1 g twice daily).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Cyclophosphamide.</head><p><s>Possible regimens included: i. Intravenous.</s><s>Minimum monthly dose 500 mg/m 2 with a recommended duration of 6-12 months.</s><s>ii.</s><s>Oral.</s><s>1-2 mg/kg/day with a recommended duration of 12 months.</s><s>Patients treated with cyclophosphamide were then usually 'transferred' to a maintenance immunosuppressive drug (methotrexate, MMF or azathioprine) as per the treating clinician's choice.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>4.</head><p><s>No immunosuppressant treatment, to give the option of including patients in whom immunosuppression was not felt indicated or appropriate (or declined by the patient).</s><s>Patients were assessed at baseline, with subsequent visits scheduled three-monthly for 24 months (or between 12 and 24 months for those patients recruited after September 2013).</s></p><p><s>To have 80% power to detect a difference between two treatment arms of five modified Rodnan skin score (mRSS) units at 12 months would require 63 patients per protocol.</s><s>Allowing 20% loss to follow-up, and varying numbers recruited to the different protocols, recruitment target was 316 patients.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Patients were recruited between July 2010 and September 2014.</s><s>Demographic characteristics including age, gender, smoking habit, ethnicity, antibody status (anti-topoisomerase-1 (anti-Scl70), anti-RNA III polymerase, anticentromere) and presence of visceral organ involvement were recorded for all patients.</s><s>The algorithms to determine the presence of different types of organ involvement are summarised in online supplementary table <ref type="table" target="#tab_1">S1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome measures</head><p><s>The primary outcome measure, assessed at each visit, was the change in mRSS over time.</s><s>All mRSS assessments were performed by those experienced in skin scoring.</s><s>The mRSS is assessed clinically at 17 body sites on a 0-3 scale (maximum score 51) and measures the extent of skin thickening. <ref type="bibr" target="#b29">13</ref></s><s>It is the most commonly used primary outcome measure in RCTs of dcSSc, <ref type="bibr">4 7 8</ref> reflecting disease severity and predicting mortality. <ref type="bibr" target="#b30">14</ref></s><s>ll other outcomes/recorded variables were mainly part of routine clinical practice and are summarised in online supplementary table <ref type="table" target="#tab_2">S2</ref>.</s><s>Secondary end points included pulmonary function (forced vital capacity (FVC: % predicted) and carbon monoxide diffusing capacity (DLCO: % predicted)), quality of life <ref type="bibr" target="#b31">[15]</ref><ref type="bibr" target="#b32">[16]</ref><ref type="bibr" target="#b33">[17]</ref><ref type="bibr" target="#b34">[18]</ref> (including the Health Assessment Questionnaire Disability Index (HAQ-DI) <ref type="bibr" target="#b31">15</ref> and Cochin Hand Function Scale <ref type="bibr" target="#b34">18</ref> ), occurrence of side effects and survival.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>In an observational study, patient characteristics differ between groups and any differences in outcomes might be driven by those characteristics rather than the treatments (confounding by indication).</s><s>In each of the analyses (for the different outcome measures), all variables associated with the outcome were considered as confounders. <ref type="bibr">19 20</ref></s><s>fferences between protocols at baseline Kruskal-Wallis test was applied for continuous variables and Fisher's test for categorical variables.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Influence of baseline characteristics on mRSS at baseline and over time</head><p><s>The association between baseline variables and mRSS was assessed by simple linear regressions, entering each characteristic separately as a predictor of mRSS.</s><s>To examine how each variable affected the progression of mRSS, the regression equation was modified by adding a term for time and its interaction with the baseline predictor value.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Differences in the changes between groups for all outcomes</head><p><s>Inverse probability of treatment (IPT) weights equalise the distributions of confounders between the treatment groups, thus removing confounding by indication. <ref type="bibr" target="#b40">21</ref></s><s>Treatment probabilities were computed using multinomial logistic regressions, with the baseline values of the selected confounders as predictors. <ref type="bibr" target="#b41">22</ref></s><s>ensoring weights rebalance the data such that the distributions of confounders remain unchanged throughout the study.</s><s>For each observation, the probability of remaining uncensored given the baseline values of the confounders, the initial protocol and a cubic spline for time was calculated using a pooled logistic regression model. <ref type="bibr" target="#b42">23</ref></s><s>Multiplying both weights yielded the IPT and inverse probability of censoring (IPTC) weights.</s><s>Weights &gt;20 were truncated at that value. <ref type="bibr" target="#b43">24</ref></s><s>reatment effects were assessed using IPTC-weighted linear regression models, which include an intercept, a time term, indicator variables for treatment groups and interactions between time and treatments.</s><s>The model followed an intention-to-treat approach.</s><s>Differences in the interaction terms reflected differences in the evolution of outcome.</s></p><p><s>Cochin hand function data were log-transformed (after adding one to each value) to correct for a highly left-skewed distribution.</s><s>CIs for the difference of logs were back-transformed, yielding a percentage difference between predicted baseline and 12-month levels.</s></p><p><s>Because of missing data at baseline for confounders, multiple imputation by chained equations was applied with STATA V.13.1.</s><s>Imputations were performed separately for each different outcome model.</s><s>Moreover, each analysis was restricted to the subset of patients with available outcome data at baseline.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival analysis</head><p><s>Kaplan-Meier curves, adjusted using IPT weights, provide estimates of the cumulative probability of surviving in each of the protocols.</s><s>An IPT-weighted Cox regression, including indicator variables for the protocols, was used to test for differences in survival between protocols.</s><s>Both overall and adverse event-free survival were examined.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>In total, 326 patients from 50 centres (19 countries) were recruited into the study (figure <ref type="figure" target="#fig_0">1</ref>): 160 from mainland Europe and the Middle East, 134 from the UK, 15 from Australia and 17 from North America (six centres from Australia and North America joined after the initial recruitment wave).</s><s>Not being a randomised study, the number of patients starting on each protocol differed: 65 (19.9%)</s><s>methotrexate, 118 (36.2%)</s><s>MMF, 87 (26.7%) cyclophosphamide and 56 (17.2%) no immunosuppressant treatment.</s><s>Median (IQR) doses are shown in online supplementary table <ref type="table">S3</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Baseline characteristics of patients</head><p><s>The median mRSS (21, IQR 16-27) and its distribution did not differ across all four treatment groups ( p=0.306) (table <ref type="table" target="#tab_0">1</ref>).</s><s>There were significant differences between treatment groups in gender ( patients in the cyclophosphamide group less likely to be female, p=0.003) and duration of skin thickening (the 'no immunosuppressant' group had the longest, p=0.001).</s><s>Also, patients in the cyclophosphamide group were more likely to have had previous immunosuppression ( p=0.007) or steroid treatment ( p=0.001).</s><s>At baseline, 94 (28.8%) patients were taking oral corticosteroids, with a median dose of 10 mg/day (range 2.5-60 mg/day).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Organ involvement</head><p><s>There were significant differences between groups for presence of pulmonary fibrosis, cardiac, renal and muscle involvement.</s><s>Patients on cyclophosphamide were more likely to have pulmonary fibrosis (p=0.036</s><s>across groups) or cardiac involvement (p=0.009</s><s>across groups).</s><s>Patients in the 'no immunosuppressant' group were more likely to have renal involvement (p=0.039), and the methotrexate group had more frequent muscle involvement ( p=0.002).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional ability</head><p><s>Scores for the HAQ-DI, Functional Assessment of Chronic Illness Therapy (FACIT) fatigue and Short-Form 36 (SF36) physical and mental indexes did not differ significantly between groups.</s><s>However, there were significant differences across groups in the cochin hand function scale (CHFS), which was poorest in the cyclophosphamide group ( p=0.025).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concomitant medications</head><p><s>As anticipated in a study of patients with early dcSSc, there was substantial use of concomitant medications (see online supplementary table <ref type="table">S4</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Progression through the study</head><p><s>Figure <ref type="figure" target="#fig_0">1</ref> shows how patients progressed through the study.</s><s>Overall, 276 patients (84.7%) remained in the study at 12 months of follow-up and 234 (71.7%) completed 24 months (or reached the last study visit date of 30 September 2015).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes in protocol</head><p><s>A total of 60 (18.4%), 12 (3.7%)</s><s>and 1 (0.3%) patients changed protocol one, two or three times during the study.</s><s>Among patients still in the study, adherence to initial protocol at 24 months for the different cohorts was 76.2% (methotrexate), 79.7% (MMF), 79.2% (cyclophosphamide) and 73.3% (no immunosuppressant) (see online supplementary figure <ref type="figure" target="#fig_0">S1</ref>).</s><s>In the no immunosuppressant cohort, 10 out of 56 patients commenced an immunosuppressant (figure <ref type="figure" target="#fig_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Withdrawals and deaths</head><p><s>In total, 35 patients (10.7%) died and 42 (12.9%)</s><s>withdrew from the study (including lost to follow-up).</s><s>Of the 35 deceased patients, 31 cases were primarily attributed to SSc-related causes (26 most likely primarily cardiorespiratory, 2 renal crises, 2 gastrointestinal (one aspiration) and 1 peritonitis (on peritoneal dialysis following renal crisis)), 3 died of cancer (1 nasopharyngeal, 1 rectal, 1 colorectal) and in 1 case the cause was unknown.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Influence of baseline variables on the initial skin score and on skin score trajectory</head><p><s>Table <ref type="table" target="#tab_2">2</ref> summarises the effect of different characteristics on the initial mRSS and its subsequent trajectory, as analysed with linear regression.</s></p><p><s>Using the associations described by table 2, the confounders identified for the skin score were age, duration of skin thickening, current or previous steroid use, anti-topoisomerase, anti-RNA polymerase III, pulmonary fibrosis, pulmonary hypertension, cardiac, renal and muscle involvement, as well as HAQ-DI, Cochin hand function and FACIT fatigue scores (see online supplementary table S5 for lists of confounders and online supplementary tables S6-S13 for each model's confounder selection process).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes in skin score over time in the different treatment groups</head><p><s>The mean change in mRSS after 12 and 24 months was −2.9 and −6.7 units.</s><s>Based on a weighted regression model, there were</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes in secondary outcomes over time in the different treatment groups Lung function</head><p><s>After adjusting for potential confounders, the change rates of FVC and DLCO were not significantly different in the four treatment groups ( p=0.460 and 0.505) (table <ref type="table">3</ref>).</s><s>However, in a subset of patients with pulmonary fibrosis or suspected pulmonary fibrosis (cases confirmed on highresolution CT (HRCT) irrespective of FVC or DLCO, or with one of the following if HRCT not performed: FVC or DLCO under 55% predicted or definite bibasal shadowing on X-ray), there was a significant difference in the change rate of FVC over time ( p=0.035).</s><s>Patients initially prescribed cyclophosphamide demonstrated 7.4% absolute increase in FVC (% predicted) compared with 2.0% decrease for methotrexate, 3.2% increase for MMF and 4.0% increase for the 'no immunosuppressant' group (table <ref type="table">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Functional ability and hand function</head><p><s>Changes over time for the HAQ-DI and CHFS did not differ between protocols ( p=0.130 and 0.073), regardless of adjusting (table <ref type="table">3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Development of internal organ involvement</head><p><s>This is described in online supplementary figure S2.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Comparison of survival between treatment protocols</head><p><s>Survival was lowest in the no immunosuppressant group at both 12 and 24 months but differences between protocols were not statistically significant either before (p=0.389) or after weighting ( p=0.440).</s><s>In the adjusted model, at 24 months, those in the no immunosuppressant group had a predicted survival rate of 84.0% compared with 94.1% for methotrexate, 88.8% for MMF and 90.1% for cyclophosphamide (figure <ref type="figure">3</ref>).</s><s>Patients with lung involvement (pulmonary fibrosis and/or hypertension) at baseline had significantly poorer survival than those without: at 24 months, their predicted survival rate was 74.6% versus 91.7% (p&lt;0.0005) and similarly for cardiac involvement, 71.6% versus 90.7% ( p&lt;0.0005).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adverse effects</head><p><s>Of the 75, 182 and 101 patients who were ever on methotrexate, MMF or cyclophosphamide, respectively, 29 (38.7%),</s><s>40 (22.0%) and 23 (22.8%) were reported to have had side effects, necessitating drug discontinuation in 9 (12.0%), 14 (7.7%) and 5 (4.5%) patients, respectively.</s><s>A survival analysis on protocol exits due to adverse effects showed no differences in the tolerability of the three treatments (p=0.212)</s><s>(see online supplementary figure <ref type="figure">S3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Our main findings were, first, that there were no significant differences in outcome between the four treatment protocols (methotrexate, MMF, cyclophosphamide, no immunosuppression), although there may be a signal in favour of immunosuppression for early dcSSc.</s><s>Although skin score improved in all treatment groups, this was least in the no immunosuppressant category, who also had the highest mortality.</s><s>Second, ESOS §Renal involvement is defined as renal crisis and/or moderate-to-severe renal impairment.</s><s>¶Despite the significant p-value for the Kruskal-Wallis test, post hoc tests reject any between-group differences in the SF36 mental scores.</s><s>** Cochin hand function scores were not performed in all centres because of translational issues.</s><s>CRP, C reactive protein; DLCO, carbon monoxide diffusing capacity; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; FACIT, Functional Assessment of Chronic Illness Therapy; FVC, forced vital capacity; GI, gastrointestinal; HAQ-DI, Health Assessment Questionnaire Disability Index; mRSS, modified Rodnan skin score (17 sites); RVSP, right ventricular systolic pressure; SF36, Short-Form 36; sPAP, systolic pulmonary artery pressure.</s></p><p><s>confirms the relative effectiveness of cyclophosphamide in patients with pulmonary fibrosis. <ref type="bibr">25 26</ref></s><s>n important point when interpreting our findings (and therefore a note of caution) is that the 'no immunosuppressant' group was not a control group.</s><s>Patients in this group had a longer disease duration than the other three groups and were more likely to have renal involvement.</s></p><p><s>Our findings lend support to two recently published studies (the Autologous Stem Cell Transplantation International Scleroderma trial (ASTIS) trial of autologous stem cell transplantation <ref type="bibr" target="#b46">27</ref> and the Scleroderma Lung Study (SLS) II (comparing MMF and cyclophosphamide), <ref type="bibr" target="#b45">26</ref> which suggest benefit, including in mRSS, from immunosuppression (as did SLS 1 <ref type="bibr" target="#b44">25</ref> ).</s><s>In ASTIS, those patients randomised to cyclophosphamide had an 8.8 unit fall in mRSS (from 25.8) at 24 months (compared with 3.3 in ESOS over 12 months), but the cyclophosphamide protocol was more intense, and the patients had more severe disease ( patients with the highest mRSS at baseline tend to improve most quickly <ref type="bibr" target="#b20">4</ref> as also demonstrated by our own findings (table <ref type="table" target="#tab_2">2</ref>)).</s><s>MRSS fell by 19.9 units in those patients randomised to stem cell transplantation <ref type="bibr" target="#b46">27</ref> (and therefore intensive immunosuppression).</s><s>In SLS 1, <ref type="bibr" target="#b44">25</ref> patients with dcSSc randomised to cyclophosphamide experienced a 5.3 unit fall in mRSS at 12 months (compared with 3.3 in ESOS), whereas mRSS fell by 1.7 on placebo (compared with 2.2 units in the ESOS 'no immunosuppressant' group).</s><s>In SLS II, <ref type="bibr" target="#b45">26</ref> mRSS at 24 months fell 4.9 units on MMF (compared with 4.1 units in ESOS at 12 months) and by 5.4 after 12 months treatment with cyclophosphamide, although these values are not directly comparable because they relate to patients with limited cutaneous and dcSSc combined.</s></p><p><s>The methodological strength of ESOS, which built upon experience gained in a previous, smaller observational study, <ref type="bibr" target="#b47">28</ref> was its design: its standardised protocols emulated the conditions of a clinical trial, and although not randomised, patients were enrolled into four homogenous treatment arms with welldefined interventions and a systematic record of protocol changes and exits.</s><s>Entry criteria were deliberately inclusive: RCTs often exclude patients with internal organ involvement and for whom immunosuppression is most likely to be Baseline predictor coefficient (95% CI) p <ref type="bibr" target="#b17">(1)</ref> Time slope (12 months) Time-predictor interaction coefficient (95% CI) p <ref type="bibr" target="#b18">(2)</ref> Age, per 10 years 0.9 (0.  Example for interpretation of results: the presence of anti-RNA polymerase III is associated with (A) a higher mRSS by 4.5 units at baseline and (B) losing an extra 2.1 units per year compared with an average of −3.0 units per year for all patients.</s><s>*Renal involvement is defined as renal crisis and/or moderate-to-severe renal impairment.</s><s>p <ref type="bibr" target="#b17">(1)</ref> : Significance p value for characteristic coefficient in linear regression of baseline mRSS on baseline predictor.</s><s>p <ref type="bibr" target="#b18">(2)</ref> : Significance p value for interaction coefficient between time and baseline characteristic in a longitudinal regression model.</s><s><ref type="table">3</ref>).</s></p><p><s>beneficial.</s><s>By recruiting 326 patients from 50 centres, ESOS represents a large cohort of patients with very early dcSSc (median duration of skin thickening 11.9 months): its data will serve as a benchmark when designing and interpreting future clinical trials.</s><s>This is especially relevant with a number of novel treatment approaches currently being explored including biological agents.</s><s>For example, in a recent RCT of tocilizumab, <ref type="bibr" target="#b48">29</ref> mRSS fell over 24 weeks by 3.9 units from 26 in the 43 tocilizumab-treated patients and by 1.2 units from 26 in the 44 placebo-treated patients, this latter fall comparable to the ESOS 'no immunosuppressant' response.</s><s>In comparing between these studies, the higher baseline mRSS in the tocilizumab study should be borne in mind.</s><s>The main weakness of observational studies is that each patient's outcome on her/his treatment arm cannot be completely disentangled from her/his initial characteristics.</s><s>For instance, ESOS has verified that patients with lung and cardiac involvement tend to be prescribed cyclophosphamide.</s><s>However, adjusting using IPT weights minimises the problem of confounding by indication.</s></p><p><s>In conclusion, observational studies offer a rich populationwide perspective assessing treatment effects in a real-world setting.</s><s>ESOS achieved its aim of following a large international cohort of patients with early dcSSc over 2 years, each of whom was treated according to one of four protocols.</s><s>The message for clinicians is that there is a weak signal to support using immunosuppressants for early dcSSc (and in particular cyclophosphamide for patients with pulmonary fibrosis).</s><s>However, it is clear that there remains a pressing need for the development of more effective and targeted treatments.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure 1 Progression of patients through the study.</s></p></div></figDesc><graphic coords="4,72.51,48.42,450.20,639.67" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure2Modified Rodnan skin score (mRSS) during baseline and follow-up visits, by initial protocol.</s><s>For each group of patients, according to their initial protocol, the distribution of the skin score is illustrated on the left-hand side by box and whisker plots (indicating the median and IQR) at baseline, 12 and 24 months.</s><s>On the right-hand side, the distribution of individual 1-year changes in the skin score is described by histograms and a kernel density estimate.</s><s>In addition, a vertical green line indicates the value of the average 1-year change in the skin score, irrespective of treatment choice.</s><s>The bottom panel in the figure describes the estimated changes in mRSS (with 95% CI) according to initial protocol, based on the results from the adjusted model (described in table3).</s></p></div></figDesc><graphic coords="9,103.58,48.42,388.06,626.74" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="10,90.65,48.42,413.97,290.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline characteristics and differences between protocols</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Protocol 4</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Protocol 1</cell><cell>Protocol 2</cell><cell>Protocol 3</cell><cell>No</cell><cell></cell><cell></cell><cell>Missing at</cell></row><row><cell></cell><cell>Methotrexate</cell><cell>Mycophenolate</cell><cell>Cyclophosphamide</cell><cell>immunosuppressant</cell><cell>P</cell><cell>Total</cell><cell>baseline,</cell></row><row><cell>Characteristic</cell><cell>n=65</cell><cell>mofetil, n=118</cell><cell>n=87</cell><cell>n=56</cell><cell>Value*</cell><cell>n=326</cell><cell>no. (%)</cell></row><row><cell>Age, years</cell><cell>52.5</cell><cell>50</cell><cell>54.1</cell><cell>52.3</cell><cell>0.324</cell><cell>52.3</cell><cell>0</cell></row><row><cell></cell><cell>(41.5-61.1)</cell><cell>(40.7-61.1)</cell><cell>(45.7-60.5)</cell><cell>(42.3-60.3)</cell><cell></cell><cell>(43-60.8)</cell><cell>(0%)</cell></row><row><cell>Female, no. (%)</cell><cell>50</cell><cell>94</cell><cell>49</cell><cell>40</cell><cell>0.003</cell><cell>233</cell><cell>0</cell></row><row><cell></cell><cell>(76.9%)</cell><cell>(79.7%)</cell><cell>(56.3%)</cell><cell>(71.4%)</cell><cell></cell><cell>(71.5%)</cell><cell>(0%)</cell></row><row><cell>Months since onset of skin thickening</cell><cell>10.3</cell><cell>12.6</cell><cell>10.2</cell><cell>16.5</cell><cell>0.001</cell><cell>11.9</cell><cell>18</cell></row><row><cell></cell><cell>(5.5-20.8)</cell><cell>(7.8-21.8)</cell><cell>(5.9-14.5)</cell><cell>(8.7-27)</cell><cell></cell><cell>(7-21)</cell><cell>(5.5%)</cell></row><row><cell>Years since onset of first non-Raynaud's</cell><cell>1.3</cell><cell>1.4</cell><cell>1.0</cell><cell>1.7</cell><cell>0.001</cell><cell>1.2</cell><cell>6</cell></row><row><cell>manifestation</cell><cell>(0.7-2.1)</cell><cell>(0.9-2)</cell><cell>(0.6-1.4)</cell><cell>(0.9-2.5)</cell><cell></cell><cell>(0.8-2)</cell><cell>(1.8%)</cell></row><row><cell>Years since onset of Raynaud's</cell><cell>1.3</cell><cell>1.9</cell><cell>1.4</cell><cell>2.2</cell><cell>0.014</cell><cell>1.7</cell><cell>22</cell></row><row><cell>phenomenon</cell><cell>(0.7-2.5)</cell><cell>(1.1-3.1)</cell><cell>(0.9-2.4)</cell><cell>(1.1-3.7)</cell><cell></cell><cell>(1-2.9)</cell><cell>(6.7%)</cell></row><row><cell>Previous immunosuppressant use, no. (%) †</cell><cell>3</cell><cell>5</cell><cell>15</cell><cell>3</cell><cell>0.007</cell><cell>26</cell><cell>0</cell></row><row><cell></cell><cell>(4.6%)</cell><cell>(4.2%)</cell><cell>(17.2%)</cell><cell>(5.4%)</cell><cell></cell><cell>(8%)</cell><cell>(0%)</cell></row><row><cell>Current or previous steroid use, no. (%)</cell><cell>33</cell><cell>39</cell><cell>51</cell><cell>18</cell><cell>0.001</cell><cell>141</cell><cell>4</cell></row><row><cell></cell><cell>(50.8%)</cell><cell>(34.2%)</cell><cell>(58.6%)</cell><cell>(32.1%)</cell><cell></cell><cell>(43.8%)</cell><cell>(1.2%)</cell></row><row><cell>Current smoker (%)</cell><cell>11</cell><cell>17</cell><cell>18</cell><cell>11</cell><cell>0.646</cell><cell>57</cell><cell>14</cell></row><row><cell></cell><cell>(16.9%)</cell><cell>(15.3%)</cell><cell>(21.7%)</cell><cell>(20.8%)</cell><cell></cell><cell>(18.3%)</cell><cell>(4.3%)</cell></row><row><cell>History of cancer, no. (%)</cell><cell>5</cell><cell>4</cell><cell>4</cell><cell>7</cell><cell>0.121</cell><cell>20</cell><cell>4</cell></row><row><cell></cell><cell>(7.8%)</cell><cell>(3.4%)</cell><cell>(4.7%)</cell><cell>(12.5%)</cell><cell></cell><cell>(6.2%)</cell><cell>(1.2%)</cell></row><row><cell>Caucasian, no. (%)</cell><cell>54</cell><cell>92</cell><cell>77</cell><cell>49</cell><cell>0.201</cell><cell>272</cell><cell>0</cell></row><row><cell></cell><cell>(83.1%)</cell><cell>(78.0%)</cell><cell>(88.5%)</cell><cell>(87.5%)</cell><cell></cell><cell>(83.4%)</cell><cell>(0%)</cell></row><row><cell>mRSS (0-51)</cell><cell>21</cell><cell>21</cell><cell>22</cell><cell>20</cell><cell>0.306</cell><cell>21</cell><cell>0</cell></row><row><cell></cell><cell>(17-24)</cell><cell>(16-27)</cell><cell>(17-29)</cell><cell>(15.5-26)</cell><cell></cell><cell>(16-27)</cell><cell>(0%)</cell></row><row><cell>Haemoglobin (g/L)</cell><cell>127</cell><cell>126</cell><cell>130</cell><cell>130</cell><cell>0.721</cell><cell>128</cell><cell>13</cell></row><row><cell></cell><cell>(118-136)</cell><cell>(118-137)</cell><cell>(116-140)</cell><cell>(118-139)</cell><cell></cell><cell>(118-137)</cell><cell>(4%)</cell></row><row><cell>White blood count (×10 9 /L)</cell><cell>7.7</cell><cell>7.9</cell><cell>8.9</cell><cell>8.0</cell><cell>0.029</cell><cell>8</cell><cell>14</cell></row><row><cell></cell><cell>(6.7-9.4)</cell><cell>(6.4-9.5)</cell><cell>(7.3-10.6)</cell><cell>(6.7-9.4)</cell><cell></cell><cell>(6.8-9.9)</cell><cell>(4.3%)</cell></row><row><cell>Platelets (×10 9 /L)</cell><cell>300</cell><cell>298</cell><cell>309</cell><cell>281</cell><cell>0.459</cell><cell>298</cell><cell>15</cell></row><row><cell></cell><cell>(254-337)</cell><cell>(246-370)</cell><cell>(259-359)</cell><cell>(250-337)</cell><cell></cell><cell>(253-358)</cell><cell>(4.6%)</cell></row><row><cell>ESR (mm/hour)</cell><cell>17</cell><cell>18</cell><cell>21</cell><cell>20</cell><cell>0.341</cell><cell>18</cell><cell>77</cell></row><row><cell></cell><cell>(10-29)</cell><cell>(8-30)</cell><cell>(9-48)</cell><cell>(10-35)</cell><cell></cell><cell>(8-34)</cell><cell>(23.6%)</cell></row><row><cell>CRP (mg/L)</cell><cell>4.0</cell><cell>5.0</cell><cell>5.9</cell><cell>4.8</cell><cell>0.026</cell><cell>5</cell><cell>90</cell></row><row><cell></cell><cell>(2.2-7.5)</cell><cell>(1.1-11)</cell><cell>(3.2-20.0)</cell><cell>(3.0-11.7)</cell><cell></cell><cell>(2.1-11.8)</cell><cell>(27.6%)</cell></row><row><cell>Anti-topoisomerase (anti-Scl70), no. (%)</cell><cell>20</cell><cell>49</cell><cell>39</cell><cell>18</cell><cell>0.228</cell><cell>126</cell><cell>7</cell></row><row><cell></cell><cell>(31.3%)</cell><cell>(42.6%)</cell><cell>(45.3%)</cell><cell>(33.3%)</cell><cell></cell><cell>(39.5%)</cell><cell>(2.1%)</cell></row><row><cell>Anti-RNA polymerase III, no. (%)</cell><cell>9</cell><cell>23</cell><cell>9</cell><cell>9</cell><cell>0.433</cell><cell>50</cell><cell>64</cell></row><row><cell></cell><cell>(18.8%)</cell><cell>(23.2%)</cell><cell>(13.0%)</cell><cell>(19.6%)</cell><cell></cell><cell>(19.1%)</cell><cell>(19.6%)</cell></row><row><cell>Anticentromere, no. (%)</cell><cell>9</cell><cell>6</cell><cell>4</cell><cell>3</cell><cell>0.147</cell><cell>22</cell><cell>12</cell></row><row><cell></cell><cell>(14.1%)</cell><cell>(5.4%)</cell><cell>(4.7%)</cell><cell>(5.7%)</cell><cell></cell><cell>(7%)</cell><cell>(3.7%)</cell></row><row><cell>Organ involvement</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pulmonary fibrosis, no. (%)</cell><cell>8</cell><cell>13</cell><cell>21</cell><cell>5</cell><cell>0.036</cell><cell>47</cell><cell>0</cell></row><row><cell></cell><cell>(12.3%)</cell><cell>(11%)</cell><cell>(24.1%)</cell><cell>(8.9%)</cell><cell></cell><cell>(14.4%)</cell><cell>(0%)</cell></row><row><cell>FVC (% predicted)</cell><cell>93.7</cell><cell>90</cell><cell>82.5</cell><cell>90</cell><cell>0.026</cell><cell>89</cell><cell>19</cell></row><row><cell></cell><cell>(81-106)</cell><cell>(75-102)</cell><cell>(68.5-96.5)</cell><cell>(75-100)</cell><cell></cell><cell>(75-102)</cell><cell>(5.8%)</cell></row><row><cell>DLCO (% predicted)</cell><cell>73</cell><cell>64.5</cell><cell>57</cell><cell>64</cell><cell cols="2">&lt;0.0005 64</cell><cell>35</cell></row><row><cell></cell><cell>(62-83)</cell><cell>(48-77)</cell><cell>(41-73)</cell><cell>(52-75)</cell><cell></cell><cell>(50-78)</cell><cell>(10.7%)</cell></row><row><cell>Pulmonary hypertension, no. (%)</cell><cell>4</cell><cell>7</cell><cell>10</cell><cell>5</cell><cell>0.488</cell><cell>26</cell><cell>1</cell></row><row><cell></cell><cell>(6.3%)</cell><cell>(5.9%)</cell><cell>(11.5%)</cell><cell>(8.9%)</cell><cell></cell><cell>(8%)</cell><cell>(0.3%)</cell></row><row><cell>sPAP or RVSP (mm Hg) ‡</cell><cell>27</cell><cell>27</cell><cell>30</cell><cell>27</cell><cell>0.472</cell><cell>29</cell><cell>124</cell></row><row><cell></cell><cell>(23-32)</cell><cell>(20-33)</cell><cell>(23-37)</cell><cell>(23-35)</cell><cell></cell><cell>(21-34)</cell><cell>(38%)</cell></row><row><cell>Cardiac involvement, no. (%)</cell><cell>5</cell><cell>8</cell><cell>19</cell><cell>7</cell><cell>0.009</cell><cell>39</cell><cell>2</cell></row><row><cell></cell><cell>(7.7%)</cell><cell>(6.8%)</cell><cell>(21.8%)</cell><cell>(13.0%)</cell><cell></cell><cell>(12%)</cell><cell>(0.6%)</cell></row><row><cell>Renal involvement, no. (%) §</cell><cell>1</cell><cell>13</cell><cell>10</cell><cell>8</cell><cell>0.039</cell><cell>32</cell><cell>0</cell></row><row><cell></cell><cell>(1.5%)</cell><cell>(11%)</cell><cell>(11.5%)</cell><cell>(14.3%)</cell><cell></cell><cell>(9.8%)</cell><cell>(0%)</cell></row><row><cell>eGFR (mL/min)</cell><cell>90</cell><cell>84.5</cell><cell>90</cell><cell>80</cell><cell>0.339</cell><cell>85</cell><cell>92</cell></row><row><cell></cell><cell>(63-90)</cell><cell>(60-90)</cell><cell>(60-90)</cell><cell>(60-90)</cell><cell></cell><cell>(60-90)</cell><cell>(28.2%)</cell></row><row><cell>Renal crisis</cell><cell>0</cell><cell>8</cell><cell>4</cell><cell>4</cell><cell>0.110</cell><cell>16</cell><cell>0</cell></row><row><cell></cell><cell>(0%)</cell><cell>(6.8%)</cell><cell>(4.6%)</cell><cell>(7.1%)</cell><cell></cell><cell>(4.9%)</cell><cell>(0%)</cell></row><row><cell>Plasma creatinine (μmol/L)</cell><cell>63.5</cell><cell>69</cell><cell>64.5</cell><cell>64</cell><cell>0.422</cell><cell>65</cell><cell>70</cell></row><row><cell></cell><cell>(55-72)</cell><cell>(55-83)</cell><cell>(53-86)</cell><cell>(56-77)</cell><cell></cell><cell>(55-79.5)</cell><cell>(21.5%)</cell></row></table><note><p><s>Continuedstatistically significant reductions in mRSS in all four treatment groups at 12 months (−4.0 (−5.2 to −2.7) units for methotrexate, −4.1 (−5.3 to −2.9) for MMF, −3.3 (−4.9 to −1.7) for cyclophosphamide and −2.2 (−4.0 to −0.3) for the no immunosuppressant group), but the differences between treatments were not significant ( p=0.346) (table 3 and figure2).</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 Continued</head><label>1</label><figDesc><div><p><s>p indicates significance of Kruskal-Wallis test (for continuous variables) or Fisher's exact test (for categorical variables).</s><s>†Of the 26 patients who had previously received immunosuppressant therapy, in 2 patients this was for cancer.</s><s>‡86 patients had a sPAP/RVSP value assumed to be normal and thus not measured.</s><s>If those cases are omitted, only 38 values of sPAP/RVSP are missing (11.7%).</s><s>Median values are 'falsely' high because calculation omits unmeasured (normal) values.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Protocol 4</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Protocol 1</cell><cell>Protocol 2</cell><cell>Protocol 3</cell><cell>No</cell><cell></cell><cell></cell><cell>Missing at</cell></row><row><cell></cell><cell>Methotrexate</cell><cell>Mycophenolate</cell><cell>Cyclophosphamide</cell><cell>immunosuppressant</cell><cell>P</cell><cell>Total</cell><cell>baseline,</cell></row><row><cell>Characteristic</cell><cell>n=65</cell><cell>mofetil, n=118</cell><cell>n=87</cell><cell>n=56</cell><cell>Value*</cell><cell>n=326</cell><cell>no. (%)</cell></row><row><cell>Any GI involvement, no. (%)</cell><cell>25</cell><cell>32</cell><cell>30</cell><cell>26</cell><cell>0.078</cell><cell>113</cell><cell>0</cell></row><row><cell></cell><cell>(38.5%)</cell><cell>(27.1%)</cell><cell>(34.5%)</cell><cell>(46.4%)</cell><cell></cell><cell>(34.7%)</cell><cell>(0%)</cell></row><row><cell>Muscle involvement, no. (%)</cell><cell>12</cell><cell>9</cell><cell>10</cell><cell>0</cell><cell>0.002</cell><cell>31</cell><cell>0</cell></row><row><cell></cell><cell>(18.5%)</cell><cell>(7.6%)</cell><cell>(11.5%)</cell><cell>(0%)</cell><cell></cell><cell>(9.5%)</cell><cell>(0%)</cell></row><row><cell>Current digital ulcers</cell><cell>10</cell><cell>17</cell><cell>17</cell><cell>11</cell><cell>0.705</cell><cell>55</cell><cell>0</cell></row><row><cell></cell><cell>(15.4%)</cell><cell>(14.4%)</cell><cell>(19.5%)</cell><cell>(19.6%)</cell><cell></cell><cell>(16.9%)</cell><cell>(0%)</cell></row><row><cell>Patient questionnaire data</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>HAQ-DI (0-3)</cell><cell>1.1</cell><cell>1</cell><cell>1</cell><cell>0.7</cell><cell>0.400</cell><cell>1</cell><cell>19</cell></row><row><cell></cell><cell>(0.4-1.8)</cell><cell>(0.5-1.6)</cell><cell>(0.4-1.9)</cell><cell>(0.1-1.5)</cell><cell></cell><cell>(0.4-1.8)</cell><cell>(5.8%)</cell></row><row><cell>FACIT fatigue score (0-52)</cell><cell>33</cell><cell>30</cell><cell>31</cell><cell>37</cell><cell>0.165</cell><cell>31</cell><cell>16</cell></row><row><cell></cell><cell>(21.5-42.5)</cell><cell>(20-37)</cell><cell>(17-40)</cell><cell>(21-44)</cell><cell></cell><cell>(20-41)</cell><cell>(4.9%)</cell></row><row><cell>SF36 physical score (0-100)</cell><cell>39.2</cell><cell>36.4</cell><cell>36</cell><cell>39.2</cell><cell>0.203</cell><cell>37.4</cell><cell>15</cell></row><row><cell></cell><cell>(30.9-45.1)</cell><cell>(30.8-43)</cell><cell>(27.2-44.5)</cell><cell>(32-48.4)</cell><cell></cell><cell>(29.9-45)</cell><cell>(4.6%)</cell></row><row><cell>SF36 mental score (0-100) ¶</cell><cell>37.2</cell><cell>36.8</cell><cell>39.5</cell><cell>40.8</cell><cell>0.029</cell><cell>38.3</cell><cell>15</cell></row><row><cell></cell><cell>(33.3-44)</cell><cell>(32.2-41.9)</cell><cell>(35.7-44.7)</cell><cell>(35.9-44.1)</cell><cell></cell><cell>(34.3-44)</cell><cell>(4.6%)</cell></row><row><cell>Cochin hand function score (0-90) **</cell><cell>11.5</cell><cell>10</cell><cell>16</cell><cell>6.5</cell><cell>0.025</cell><cell>11</cell><cell>96</cell></row><row><cell></cell><cell>(2-30.5)</cell><cell>(4-24)</cell><cell>(5-40)</cell><cell>(0-23)</cell><cell></cell><cell>(3-29)</cell><cell>(29.4%)</cell></row><row><cell>Median (IQR) unless otherwise indicated.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>*</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2</head><label>2</label><figDesc><div><p><s>Associations between baseline characteristics and skin score</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell>(A) Association with baseline mRSS</cell><cell>(B) Effect on mRSS evolution</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">on May 17, 2022 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/annrheumdis-2016-210503 on 10 February 2017. Downloaded from</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Acknowledgements The authors are grateful to Dr Holly Ennis for study set-up and to her and Dr Graham Dinsdale for project coordination during the earlier phases of the study.</s><s>Thanks also to members of the independent oversight board: Stephen Cole, Dinesh Khanna and Frank Wollheim.</s></p><p><s>Contributors ALH, ML, RH, LM, AS, EB, LC, JHWD, OD, KF, WJG, RO, MV and CPD were members of the Steering Committee and designed the study.</s><s>ALH, RH, LM, LC, JHWD, OD, MV, CA, VHO, DF, MH, MM-C, AB-G,OM, ACJ, PJ, WS, PM, FCH, CA, MEA, ED, RM, MA, MHB, LC, ND, HG, PL, YA, KC, SJ, AJM, NM, UM-L, GR, MB, JR, PEC, AF, EH, JH, MI, JSM, J van L, SP, SP, AR, JS, BC, CS, TS, DJV, CG, GT and CPD were principal investigators at the different sites and recruited patients.</s><s>XP was study coordinator.</s><s>SP and ML were responsible for the statistical analysis.</s><s>ALH, XP, SP, ML, RH, LM, AS and CPD wrote the draft report, and all authors reviewed the report, provided comments and approved the final report.</s></p><p><s>Funding ESOS was funded by a grant from the European League Against Rheumatism (EULAR) Orphan Disease Programme.</s><s>Additional funding from Scleroderma and Raynaud's UK allowed a 1-year extension of the study.</s></p><p><s>Competing interests ALH has done consultancy work for Actelion, served on a Data Safety Monitoring Board for Apricus, received research funding and speaker's fees from Actelion, and speaker's fees from GSK. JHWD has consultancy relationships and/or has received research funding from Actelion, BMS, Celgene, Bayer Pharma, Boehringer Ingelheim, JB Therapeutics, Sanofi-Aventis, Novartis, UCB, GSK, Array Biopharma, Active Biotech, Galapagos, Inventiva, Medac, Pfizer, Anamar and RuiYi and is stock owner of 4D Science GmbH.</s><s>OD has received consultancy fees from 4D Science, Actelion, Active Biotech, Bayer, Biogenidec, BMS, Boehringer Ingelheim, EpiPharm, Ergonex, espeRare Foundation, Genentech/Roche, GSK, Inventiva, Lilly, Medac, Medimmune, Pharmacyclics, Pfizer, Serodapharm, and Sinoxa and received research grants from Actelion, Bayer, Boehringer Ingelheim, Ergonex, Pfizer and Sanofi, and has a patent mir-29 for the treatment of systemic sclerosis licenced.</s><s>WG has received teaching fees from Pfizer.</s><s>FH has received research funding from Actelion.</s><s>MEA has undertaken advisory board work and received honoraria from Actelion, and received speaker's fees from Bristol-Myers Squibb.</s><s>LC has done advisory board work for Gilead and served Data Safety Monitoring Boards for Cytori and Reata.</s><s>HG has done consultancy work and received honoraria from Actelion.</s><s>UM-L is funded in part bu EUSTAR/EULAR.</s><s>JMvL has received honoraria from Eli Lilly, Pfizer, Roche, MSD and BMS.</s><s>AR receives funding from AstraZeneca.</s><s>CPD has done consultancy for GSK, Actelion, Bayer, Inventiva and Merck-Serono, received research grant funding from GSK, Actelion, CSL Behring and Inventiva, received speaker's fees from Bayer and given trial advice to Merck-Serono.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient consent Obtained.</head><p><s>Ethics approval The Ethics Committee of each centre approved the study.</s></p><p><s>Provenance and peer review Not commissioned; externally peer reviewed.</s></p><p><s>Data sharing statement At present, unpublished data from the study are not available for sharing.</s><s>This position may change in 6-12 months time.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Table <ref type="table">3</ref> Predicted yearly changes in outcomes and survival rates according to initial protocol, with and without adjusting (95% CI)</s></p><note type="other">Outcome</note></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1207" to="1218" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503on10</idno>
		<imprint>
			<date type="published" when="2017-02">February 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1207" to="1218" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503on10</idno>
		<imprint>
			<date type="published" when="2017-02">February 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Adjusting for confounding</title>
		<imprint>
			<biblScope unit="page">326</biblScope>
		</imprint>
	</monogr>
	<note>weighted model</note>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Significance p: Fisher&apos;s test for equality of change rates between protocols, for each outcome variable</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">To obtain 24-month changes, multiply results above by 2. †For the subanalysis involving the subset of patients with pulmonary fibrosis at baseline, patients with definite bibasal pulmonary fibrosis confirmed on HRCT were included, irrespective of FVC value. If no HRCT scan was performed at baseline, an FVC&lt;55%, DLCO&lt;55% predicted or definite bibasal shadowing on X-ray was also a basis for inclusion. ‡Changes expressed in units for the Cochin regression are an approximation derived from the 95% CI of percentage changes between baseline and 12 months</title>
	</analytic>
	<monogr>
		<title level="m">*Results are reported in terms of changes after 12 months</title>
				<imprint/>
	</monogr>
	<note>However, all study data (from baseline to the 24-month end point) were used in estimation. applied to the predicted baseline values for each group in the original scale</note>
</biblStruct>

<biblStruct xml:id="b9">
	<monogr>
		<title level="m" type="main">DLCO, carbon monoxide diffusing capacity; FVC, forced vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; HRCT, high-resolution CT; mRSS</title>
		<imprint/>
	</monogr>
	<note>modified Rodnan skin score (17 sites</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title/>
		<author>
			<persName><surname>Pf</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1207" to="1218" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503on10</idno>
		<imprint>
			<date type="published" when="2017-02">February 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1207" to="1218" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b16">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503on10</idno>
		<imprint>
			<date type="published" when="2017-02">February 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Epidemiology of systemic sclerosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nikpour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.berh.2010.10.007</idno>
	</analytic>
	<monogr>
		<title level="j">Best Practice Res Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="857" to="869" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Mortality and survival in systemic sclerosis : systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Rubio-Rivas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Royo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Simeon</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.semarthrit.2014.05.010</idno>
	</analytic>
	<monogr>
		<title level="j">Sem Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="208" to="219" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Prediction of pulmonary complications and long-term survival in systemic sclerosis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">I</forename><surname>Nihtyanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">H</forename><surname>Ong</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.38390</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="1625" to="1635" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Merkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Silliman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.34427</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="3420" to="3429" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">From randomized controlled trials to observational studies</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Silverman</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amjmed.2008.09.030</idno>
	</analytic>
	<monogr>
		<title level="j">Am J Med</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="114" to="120" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">The continuing unethical conduct of underpowered clinical trials</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Halpern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Karlawish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Berlin</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.288.3.358</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="358" to="362" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Pope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bellamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Seibold</surname></persName>
		</author>
		<idno type="DOI">10.1002/1529-0131(200106)44:6&lt;1351::AID-ART227&gt;3.0.CO;2-I</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="1351" to="1358" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicentre, randomized, placebo-controlled Phase I/II trial of CAT-192</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Merkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Furst</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.22289</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="323" to="323" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR)</title>
		<author>
			<persName><forename type="first">O</forename><surname>Kowal-Bielecka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Landewé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Avouac</surname></persName>
		</author>
		<idno type="DOI">10.1136/ard.2008.096677</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="620" to="628" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<monogr>
		<title level="m" type="main">The Harveian Oration of 2008: On the evidence for decisions about the use of therapeutic interventions. London: Royal College of Physicians</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Rawlins</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Innovative research methods for studying treatments for rare diseases: methodological review</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gagne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>O'keefe</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmj.g6802</idno>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page">6802</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Scleroderma (systemic sclerosis): classification, subsets and pathogenesis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Leroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fleischmajer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="202" to="205" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Inter-and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Clements</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lachenbruch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Siebold</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1281" to="1285" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Skin thickness score as a predictor and correlate of outcome in systemic sclerosis</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Hurwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Wong</surname></persName>
		</author>
		<idno type="DOI">10.1002/1529-0131(200011)43:11&lt;2445::AID-ANR11&gt;3.0.CO;2-Q</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="2445" to="2454" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Steen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Medsger</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.1780401110</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1984" to="1991" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation</title>
		<author>
			<persName><forename type="first">K</forename><surname>Webster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yost</surname></persName>
		</author>
		<idno type="DOI">10.1186/1477-7525-1-79</idno>
	</analytic>
	<monogr>
		<title level="j">Health Qual Life Outcomes</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">79</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Measuring fatigue in SSc: a comparison of the Short Form-36 Vitality subscale and Functional Assessment of Chronic Illness Therapy-Fatigue scale</title>
		<author>
			<persName><forename type="first">D</forename><surname>Harel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Thombs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hudson</surname></persName>
		</author>
		<idno type="DOI">10.1093/rheumatology/kes206</idno>
	</analytic>
	<monogr>
		<title level="j">Rheumatol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="2177" to="2185" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<monogr>
		<title level="m" type="main">Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rannou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Poiraudeau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berezne</surname></persName>
		</author>
		<imprint>
			<biblScope unit="page">1217</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Herrick</surname></persName>
		</author>
		<idno type="DOI">10.1136/annrheumdis-2016-210503</idno>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="1207" to="1218" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<monogr>
		<title level="m" type="main">Clinical and epidemiological research on May 17, 2022 by guest</title>
		<imprint/>
	</monogr>
	<note>Protected by copyright</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey</title>
		<author>
			<persName><forename type="first">Ann</forename><surname>Rheum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dis</forename></persName>
		</author>
		<idno type="DOI">10.1002/art.22468</idno>
	</analytic>
	<monogr>
		<title level="j">Downloaded from Assessment Questionnaire (HAQ)</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="94" to="102" />
			<date type="published" when="2007">February 2017. 2007</date>
		</imprint>
	</monogr>
	<note>Arthritis Rheum</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Variable selection for propensity score models</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Brookhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schneeweiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Rothman</surname></persName>
		</author>
		<idno type="DOI">10.1093/aje/kwj149</idno>
	</analytic>
	<monogr>
		<title level="j">Amer J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="1149" to="1156" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Austin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grootendorst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-Lt</forename><surname>Normand</surname></persName>
		</author>
		<idno type="DOI">10.1002/sim.2618</idno>
	</analytic>
	<monogr>
		<title level="j">Stat Med</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="754" to="768" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Marginal structural models as a tool for standardization</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsuyama</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.EDE.0000081989.82616.7d</idno>
	</analytic>
	<monogr>
		<title level="j">Epidemiology</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="680" to="686" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">The role of the propensity score in estimating dose-response functions</title>
		<author>
			<persName><forename type="first">G</forename><surname>Imbens</surname></persName>
		</author>
		<idno type="DOI">10.1093/biomet/87.3.706</idno>
	</analytic>
	<monogr>
		<title level="j">Biometrika</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page" from="706" to="710" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Controlling for time-dependant confounding using marginal structural models</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Fewell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hernan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wolfe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stata J</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="402" to="420" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Constructing inverse probability weights for marginal structural models</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hernán</surname></persName>
		</author>
		<idno type="DOI">10.1093/aje/kwn164</idno>
	</analytic>
	<monogr>
		<title level="j">Amer J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="656" to="664" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Cyclophosphamide versus placebo in scleroderma lung disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Tashkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Elashoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa055120</idno>
	</analytic>
	<monogr>
		<title level="j">N Eng J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="2655" to="2666" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomsed controlled, double-blind, parallel group trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Tashkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Clements</surname></persName>
		</author>
		<idno type="DOI">10.1016/S2213-2600(16)30152-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Respir Med</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="708" to="719" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Van Laar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Farge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Sont</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2014.6368</idno>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="page" from="2490" to="2498" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Herrick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Whidby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="116" to="124" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><surname>Khanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Denton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jahreis</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(16)00232-4</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="page" from="2630" to="2640" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
